Haisco(SZ:002653) Zheng Quan Shi Bao·2026-01-06 18:15Core Insights - Haisco has transformed from a specialized pharmaceutical company to an integrated innovative drug research, production, and sales group since its establishment in 2000, focusing on key therapeutic areas such as anesthesia, respiratory, and chronic diseases [1][2] - The company has developed a diversified pipeline of innovative drugs, with several projects like HSK31858 and HSK39297 in late-stage clinical development, and its first innovative drug,环泊酚, received FDA acceptance for listing in the U.S. in July 2025 [1][2] Financial Performance - In Q3 2025, Haisco achieved a revenue of 3.3 billion yuan, representing a year-on-year growth of 19.95% [1] - By the end of 2025, Haisco's market capitalization reached 57.5 billion yuan, ranking first in the Tibet region [1] Capital Operations - In February 2023, Haisco raised 800 million yuan through its first private placement to support the approval and inclusion of two innovative drugs,考格列汀片 and 苯磺酸克利加巴林胶囊, in the medical insurance system by 2024 [1] - The company has established a full-process technical system from early drug discovery to commercialization, enabling rapid product volume growth through academic marketing and channel integration [2] Investor Relations - Haisco has implemented a shareholder return plan for 2025-2027, committing to annual cash dividends of no less than 10% of the distributable profits or a cumulative cash dividend of no less than 30% of the average net profit over the last three years [2] - Since its listing, Haisco has distributed over 3.67 billion yuan in cash dividends, achieving a dynamic balance between corporate development and shareholder returns [2] Future Outlook - Haisco aims to continue focusing on the core innovative drug sector, leveraging its full-process R&D platform and capital operations to accelerate the implementation of ongoing projects and strengthen its international market presence [2]